Axsome Therapeutics vs Harmony Biosciences Holdings
Harmony Biosciences Holdings is the larger business, with $868m of revenue in fiscal 2025 against $638m for Axsome Therapeutics (1.4 times as much). Axsome Therapeutics grew faster (65.5% against 21.5%). Harmony Biosciences Holdings kept more of each dollar of sales as profit: a net margin of 18.3% against -28.7%. Harmony Biosciences Holdings carries less debt relative to equity (19.0% against 212.6%).
| Latest fiscal year | Axsome TherapeuticsAXSM, 2025 | Harmony Biosciences HoldingsHRMY, 2025 |
|---|---|---|
| Revenue | $638m | $868m |
| Revenue growth | 65.5% | 21.5% |
| Net income | −$183m | $159m |
| Operating margin | -26.1% | 24.0% |
| Net margin | -28.7% | 18.3% |
| Return on equity | — | 20.8% |
| Free cash flow | −$93.9m | $348m |
| Cash | $323m | $753m |
| Total debt | $188m | $165m |
| Debt to equity | 212.6% | 19.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 293 |
| Market value | $7.38bn | $2.14bn |
| Price vs our value range | — | Below our value range |
| Moat score | — | 93 (Strong) |
| Insider trades, 12 months | 0 buys, 33 sales | 0 buys, 13 sales |